Business
Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical
About this update from Axogen, Inc.
[{"type":"text","content":"ALACHUA, Fla. and TAMPA, Fla., March 24, 2025 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today announced the appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy. Mr. Ditto will report to Michael Dale, President, and Chief Executive Officer, and will lead the development of the coverage and reimbursement-related strategies required to support Axogen’s mission to establish restoration of peripheral nerve function as an expected standard of care. Mr. Ditto brings over 15 years of leadership experience in the medical device industry, with a proven track record at Zimmer Biomet, Johnson & Johnson, and as the first employee at Lumere (acquired by GHX). He has deep expertise in facility economics and payor strategy, including developing approaches to optimize reimbursement and navigate complex payor environments. Mr. Ditto earned his Bachelor of Science in Biomedical Engineering at Case Western Reserve University, his Master of Science, Bioengineering at The University of Toledo, and a Master of Science, Applied Health Economics & Outcomes Research at Thomas Jefferson University. “We are delighted to welcome Rick to the Axogen team,” said Michael Dale, Chief Executive Officer, and Director, Axogen. “His strong payor relationships and extensive experience in health economics, reimbursement and policy will be critical assets for Axogen to build upon as we work to make restoration of peripheral nerve function an expected standard of care.” Notice of Issuance of Inducement Grant In connection with the commencement of his employment on March 24, 2025, and as a material inducement of employment, Mr. Ditto will be awarded an equity grant on April 1, 2025, consisting of a non-qualified equity grant in the form of Restricted Stock Units (RSU) for the grant of 45,000 shares of Axogen, Inc. common stock. The shares representing the RSUs are subject to vesting over 4 years, with 50% vesting after the second year and 25% of the total shares granted vesting every year thereafter for the next two years. About Axogen Axogen (AXGN) is the leading Company focused specifically on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees ...